PBI-05204
Glioblastoma, Pancreatic Cancer, Solid Tumors
Phase 2Active
Key Facts
Indication
Glioblastoma, Pancreatic Cancer, Solid Tumors
Phase
Phase 2
Status
Active
Company
About Phoenix Biotechnology
Phoenix Biotechnology is a private, clinical-stage company leveraging the bioactive compounds of the Nerium oleander plant to develop novel therapeutics for oncology, virology, and neurodegeneration. Its lead candidate, PBI-05204, has progressed to Phase II trials for glioblastoma and other cancers, demonstrating a unique mechanism of action involving FGF-2 inhibition and immune modulation. The company's strategy targets high-unmet-need indications with a natural product-derived platform, aiming for safer, more affordable treatments, though it faces challenges typical of botanical drug development and early-stage biotechs.
View full company profile